Comparison of the Efficacy of Atopalm® Multi-Lamellar Emulsion Cream and Physiogel® Intensive Cream in Improving Epidermal Permeability Barrier in Sensitive Skin

Sekyoo Jeong · Sin Hee Lee · Byeong Deog Park · Yan Wu · George Man · Mao-Qiang Man

To view enhanced content go to www.dermtherapy-open.com
Received: December 30, 2015 / Published online: February 3, 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

ABSTRACT

Introduction: The management of sensitive skin, which affects over 60% of the general population, has been a long-standing challenge for both patients and clinicians. Because defective epidermal permeability barrier is one of the clinical features of sensitive skin, barrier-enhancing products could be an optimal regimen for sensitive skin. In the present study, we evaluated the efficacy and safety of two barrier-enhancing products, i.e., Atopalm® Multi-Lamellar Emulsion (MLE) Cream and Physiogel® Intensive Cream for sensitive skin.

Methods: 60 patients with sensitive skin, aged 22–40 years old, were randomly assigned to one group treated with Atopalm MLE Cream, and another group treated with Physiogel Intensive Cream twice daily for 4 weeks. Lactic acid stinging test scores (LASTS), stratum hydration (SC) and transepidermal water loss (TEWL) were assessed before, 2 and 4 weeks after the treatment.

Results: Atopalm MLE Cream significantly lowered TEWL after 2 and 4 weeks of treatment \((p < 0.01)\). In contrast, Physiogel Intensive Cream significantly increased TEWL after 2 weeks of treatment \((p < 0.05)\) while TEWL significantly decreased after 4-week treatments. Moreover, both Atopalm MLE Cream and Physiogel Intensive Cream significantly increased SC hydration, and improved LASTS after 4 weeks of treatment.

Conclusion: Both barrier-enhancing products are effective and safe for improving epidermal functions, including permeability barrier, SC hydration and LASTS, in sensitive skin. These products could be a valuable alternative for management of sensitive skin.

Funding: Veterans Affairs Medical Center, San Francisco, California, USA, and NeoPharm Co., Ltd., Daejeon, Korea.
Keywords: Atopalm; Epidermal permeability barrier; Physiogel; Sensitive skin; Stratum corneum hydration

INTRODUCTION

Sensitive skin is a skin condition that is hypersensitive to various external stimuli. The prevalence of sensitive skin in the general population is over 60% in both males and females [1]. In the general population, over 50% have suffered sensitive skin for over 5 years, and more than 42% have over a 10-year history of sensitive skin [2]. In over 30% of this population their sensitive skin worsened [2]. The prevalence rate is higher in African-Americans than in Caucasians, particularly in the genital area [1, 3]. On the face and genital area, females have a higher prevalence than males [1]. Sensitive skin can be caused by a variety of external and internal factors, including sun exposure, psychological stress, wind and hot or cold weather conditions [1]. Among these factors, use of cosmetic products is the most common cause [4]. For example, use of inappropriate washing emulsion can elevate both skin surface pH and transepidermal water loss (TEWL) [5] which in turn can induce or exacerbate cutaneous inflammation [6–9]. Certain dermatoses, such as atopic dermatitis, are associated with sensitive skin [4].

The prevention and treatment of sensitive skin have been a challenge for both patients and clinicians due to its uncertain etiology and pathogenesis. However, sensitive skin features a number of abnormalities in its biophysical properties, including increased TEWL and skin erythema index, reduced stratum hydration (SC), and compromised SC integrity. Cho et al. did, however, show no difference in TEWL between sensitive skin and normal skin [10–13]. Moreover, a marked elevation in both skin surface pH and TEWL are observed in subjects with sensitive skin following topical application of lactic acid [14, 15]. Among these changes, increased TEWL, indicating a disrupted permeability barrier, has significant impact on cutaneous function. First, disruption of permeability barrier induces cutaneous inflammation via stimulation of proinflammatory cytokine release [16–20], inflammatory cell maturation and infiltration [9, 21–23] while inflammation is a pathophysiological feature of sensitive skin [24]. Second, barrier disruption increases the density of mast cell, a major source of histamine, in the dermis [7] whereas release of histamine can cause itching upon external stimuli [25]. The increased histamine could further disrupt epidermal permeability barrier via inhibition of keratinocyte differentiation and lipid production [26, 27]. Third, compromised permeability barrier increases cutaneous sensitivity to allergens through facilitation of allergen penetration [28] while increased transcutaneous penetration of substances is another feature of sensitive skin [29–31]. Taken together, compromised epidermal permeability barrier plays a crucial role in the pathogenesis of sensitive skin. Therefore, the strategies to enhance epidermal permeability barrier have been recommended by experts for the management of sensitive skin [32, 33]. However, the availability of barrier-enhancing products for sensitive skin is still limited. In the present study, we compared the efficacy of Physiogel® Intensive Cream (Stiefel Laboratories, Inc. Middlesex, UK) and Atopalm® Multi-Lamellar Emulsion (MLE) Cream (NeoPharm Co., Ltd, Daejeon, Korea) for improving epidermal permeability barrier in Chinese with sensitive skin.
METHODS

Subjects

A randomized, double-blind controlled clinical trial was conducted in 60 Chinese females with sensitive skin in an outpatient clinic. The inclusion criteria included Chinese female, aged 20–40 years old, with sensitive skin, and Lactic Acid Sting Test (LAST) score ≥3 at 2.5 and 5 min. The exclusion criteria included pregnant women, nursing mothers, women planning to be pregnant in the next 3 months, receiving or going to receive any medications or any cosmetology treatments within the last 3 months and during the study period, direct facial exposure to sunlight or artificial UV irradiation without protection over the last 2 h, known allergic or sensitive to any ingredients in the test products and not using any other products during the study period (excluding lipstick, eyeliner or eye shadow). All subjects were non-atopic and with no skin disorders which are known to influence epidermal function. Informed consent was obtained from all individual participants in the study. Subjects were alternately assigned to group A or B after completion of consent form. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The protocol of this study was approved by human research committee of Peking University First Hospital, Beijing, China.

LAST

LAST was performed by applying 50 μl of 5% lactic acid solution with two layers of filter paper (diameter 0.5 cm) to the nasolabial folds. Skin stinging was evaluated by a 4-point scale (0, absence of stinging; 1, weak stinging; 2, moderate stinging; 3, strong stinging) 0, 2.5, 5 and 8 min after the application.

Materials and Treatments

30 subjects in group A were treated with Atopalm MLE Cream while 30 subjects in group B were treated with Physiogel Intensive Cream twice daily for 4 weeks. The major active ingredients in these two products are detailed in Table 1. Products were only applied to the face. This study was carried out at the Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China, between April and August 2015.

Table 1  List of major active ingredients

| Physiogel® intensive cream [34] | Atopalm® MLE cream[a] |
|-------------------------------|----------------------|
| **Glycerin**                  | Glycerin             |
| **Butyrospermum parkii**      | *Vitis vinifera* (Grape) seed oil |
| **Squalane**                  | *Simmondsia chinensis* (Jojoba) seed oil |
| **Pentylene glycol**          | Olea europaea (Olive) fruit oil |
| **Cocos nucifera oil**        | Portulaca oleracea extract |
| **Ceramide 3**                | Phytosterols         |
|                               | Sodium hyaluronate   |
|                               | Arginine             |
|                               | Tocopheryl acetate   |
|                               | Myristoyl/palmitoyl oxostearamide/arachamide MEA |

MLE multi-lamellar emulsion

[a] Information was provided by NeoPharm Co., Ltd., Daejeon, Korea
Assessment of Efficacy

TEWL, an indicator of epidermal permeability barrier function, was measured using a TewaMeter® TM210 (Courage + Khazaka electronic GmbH, Cologne, Germany) while SC capacitance, an indicator of SC hydration, was measured on the right zygomatic area using a Corneometer® CM 825 (Courage + Khazaka electronic GmbH, Cologne, Germany) before, 14 and 28 days after treatments. Meanwhile, the LAST was also performed on the nasolabial folds. All tests were carried out under controlled environmental conditions at the humidity of 40 ± 10% and temperature of 22 ± 2 °C. Subjects rested peacefully in such environment for at least 30 min before the tests.

Assessment of Adverse Event

Adverse events were assessed 2 and 4 weeks after treatments, using following numerical grading system: 0, no adverse event; 1, occasionally mild; 2, moderate, but endurable; 3, severe, with predominant symptoms. Subjects with adverse reaction ≥grade 2 were asked to discontinue the trial.

Statistical Analyses

Data are expressed as mean ± SEM except otherwise indicated in the text. Data were analyzed using GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). Nonparametric two-tailed T test was used to determine significant differences between two groups.

RESULTS

Out of 60 subjects, one subject experienced facial redness after application of Atopalm MLE Cream. The subject refused to have a patch test.

Table 2  Demographic data of subjects

| Group | Number | Age range (years) | Mean | SD |
|-------|--------|-------------------|------|----|
| Group A | 29 | 24–40 | 28 | 4.38 |
| Group B | 30 | 22–40 | 30.8 | 6.79 |

SD standard deviation

The lesion disappeared 1 day after discontinuation of using the cream. The remaining 59 subjects completed the trial with no sign of adverse reaction. The demographic data of these subjects were detailed in Table 2.

Both Products Improve Epidermal Permeability Barrier

Since Atopalm MLE Cream and Physiogel Intensive Cream contain stratum corneum lipids, which benefit the epidermal permeability barrier [35–37], we first assessed epidermal permeability barrier function after topical applications of these products. As shown in Fig. 1a, topical applications of Atopalm MLE Cream for 2 weeks induced an over 20% reduction in TEWL. In contrast, Physiogel Intensive Cream caused an 11% increase in TEWL after 2 weeks of treatment. After 4 weeks of treatments, both Atopalm MLE Cream and Physiogel Intensive Cream benefited the epidermal permeability barrier while the reduction in TEWL was more dramatic in Atopalm MLE Cream-treated than in Physiogel Intensive Cream-treated subjects.

Our prior studies have demonstrated that topical stratum corneum lipids or their containing product improve stratum corneum hydration [38–40], which is reduced in sensitive skin [10]. We next determined whether topical treatments with these products also improve stratum corneum hydration in sensitive skin. Indeed, both products significantly increased stratum corneum hydration after 4 weeks of treatment although the improvement of
Stratum corneum hydration was not dramatic after 2 weeks of treatment (Fig. 1b). The improvement in stratum corneum hydration was no different between these two products after 2 or 4 weeks of treatment. Taken together, these results demonstrated that topical applications of either product improves epidermal permeability barrier and stratum corneum hydration in subjects with sensitive skin.

Both Products Improve LASTS

Sensitive skin is characterized by an enhanced response to LAST [30, 31], which is likely due to poor permeability barrier that facilitates the penetration of lactic acid into skin [28, 29]. Since both Atopalm MLE Cream and Physiogel Intensive Cream improved epidermal permeability barrier, we next assessed whether these two products also improve LAST scores. As seen in Fig. 2, after 2 weeks of treatments with these products, LAST scores were reduced by 14%. Further reductions in LAST scores were observed after 4 weeks of treatment (27.3 ± 7.2% for Atopalm MLE Cream and 34.1 ± 8% for Physiogel Intensive Cream, no significant difference was observed between these two products). These results demonstrate that Atopalm MLE Cream- and Physiogel Intensive Cream-induced improvement of permeability barrier is paralleled by a reduction in LAST scores.

---

Fig. 1 The effects of barrier-enhancing products on the epidermal permeability barrier in subjects with sensitive skin. Subjects’ faces with sensitive skin were treated with either Atopalm® MLE Cream or Physiogel® Intensive Cream twice daily for 4 weeks. TEWL and stratum corneum hydration were measured before, 2 and 4 weeks after treatments as described in ‘Methods’. a Depicts the influences of topical products on TEWL after 2 and 4 weeks of treatments. b Displays the effects of topical products on stratum corneum hydration after 2 and 4 weeks of treatments. For both TEWL and stratum corneum hydration, the data were expressed as % changes from baseline. Significances and number of subjects are indicated in the figures. MLE multi-lamellar emulsion, SC stratum hydration, TEWL transepidermal water loss

Fig. 2 The effects of barrier-enhancing products on LASTS in subjects with sensitive skin. Subjects’ faces with sensitive skin were treated with either Atopalm® MLE Cream or Physiogel® Intensive Cream twice daily for 4 weeks. LASTS was performed before, 2 and 4 weeks after treatments as described in ‘Methods’. Skin stinging was evaluated by a 4-point scale. The data were expressed as % improvement from baseline. Significances and number of subjects are indicated in the figures. LASTS lactic acid sting test scores, MLE Multi-Lamellar Emulsion
DISCUSSION

Sensitive skin is a common skin disorder. The preventive and therapeutic regimens are limited although moisturizers are available [41–43]. In the present study, we showed that topical applications of these two products improved LAST scores, likely resulting from enhanced epidermal permeability barrier function in subjects with sensitive skin. Although both products contain stratum corneum lipids, which are known to improve epidermal permeability barrier in both normal and diseased skin [36, 37, 44], topical Atopalm MLE Cream induced a rapid improvement in epidermal permeability barrier after 2 weeks of treatment. In contrast, Physiogel Intensive Cream increased TEWL after 2 weeks of treatment. The mechanisms underlying the difference in the efficacy between the two products are unclear. However, several potential variations in the formulations could affect the efficacy. First, the effects of stratum corneum lipid mixture on epidermal permeability barrier are largely determined by the molar ratio of these lipids [36]. The molar ratio of these lipids could be different between these two products. Second, the composition of the lipid mixture can also affect the efficacy of the products. For example, linoleic acid is not only the structural requirement for barrier formation, but also activates peroxisome proliferator-activated receptor γ (PPAR γ) [45]. Activation of PPARγ stimulates epidermal lipid production and differentiation, both of which benefit epidermal permeability barrier [46]. The content of linoleic acid in cocos nucifera oil and butyrospermum parkii, sources of linoleic acid in Physiogel Intensive Cream, ranges 3–11% [47, 48] while olea europaea (Olive) fruit oil and vitis vinifera seed oil, ingredients in Atopalm MLE Cream, are enriched in linoleic acid (as high as over 70%) [49]. Third, both antioxidant (tocopheryl acetate) and hyaluronate, ingredients in Atopalm MLE Cream, benefit the epidermal permeability barrier [50–52]. Moreover, myristoyl/palmitoyl oxostearamide/arachamide MEA upregulates epidermal PPARα expression [53]. The latter is crucial for maintenance of epidermal permeability barrier function [54]. Moreover, activation of either PPARα or PPARγ inhibits cutaneous inflammation, which is a feature of sensitive skin [46, 55]. Thus, the different efficacy of these two products could be attributed to their compositional differences.

Although there were no untreated controls in the present study, the reduced TEWL value unlikely reflected spontaneous remission of disease due to the changes in humidity and/or environmental temperature. The study was carried from April (low humidity, spring) to August (high humidity, summer) during which environmental humidity and temperature gradually increased. Previous studies have shown that TEWL levels are lower in low humidity than in high humidity in both mice and humans [56, 57]. TEWL levels in humans are higher in summer than in winter [58]. However, our results show that TEWL levels were reduced after treatment. Thus, the reduction in TEWL is likely attributable to the products.

Previous studies have shown that disruption of the epidermal permeability barrier enhances percutaneous penetration of a substance [59, 60], and that enhancement of the epidermal permeability barrier can decrease cutaneous response to irritants [61] and improve inflammation [44]. In addition to facilitating percutaneous penetration of substances, a compromised permeability barrier alone can also provoke inflammation in sensitive skin. Thus, improved barrier function induced by
these two products may not only alleviate inflammation, but may also prevent substances from penetrating the skin, suggesting potential utilization of these products for the prevention and treatment of sensitive skin. The present study also showed that both products increased stratum corneum hydration, which is low in sensitive skin. Previous studies have demonstrated that moisturizers improve sensitive skin. Hence, the beneficial effect of these two products on stratum corneum hydration provides another rationale for their usage in treating sensitive skin. However, whether other products, such as diaper cream, cis-Urocanic Acid emulsion cream and Canoderm that improves epidermal permeability barrier in humans [62–64], also benefits sensitive skin, remains to be determined. Moreover, further clinical studies are required to validate the efficacy and safety of these products before they are widely recommended to patients with sensitive skin.

CONCLUSION

Barrier-enhancing products such as Atopalm MLE Cream and Physiogel Intensive Cream are effective for improving the epidermal permeability barrier, stratum corneum hydration and LAST scores. The benefits of barrier-enhancing products means that barrier-enhancing strategies could be a valuable approach for preventing and treating sensitive skin.

ACKNOWLEDGMENTS

Sponsorship for this study was funded in part by the resources and facilities at the Veterans Affairs Medical Center, San Francisco, California, USA, and NeoPharm Co., Ltd., Daejeon, Korea, which sponsored graduate students from Peking University to perform the study. Article processing charges were funded by NeoPharm Co., Ltd., Daejeon, Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Disclosures. Man G and Man MQ have nothing to disclose. Jeong S, Lee SH and Park BD were employees of NeoPharm Co., Ltd., Daejeon, Korea. Wu Y received funding from NeoPharm Co for supporting graduate students to perform the study.

Compliance with ethics guidelines. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The protocol of this study was approved by human research committee of Peking University First Hospital, Beijing, China. Informed consent was obtained from all individual participants in the study.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
REFERENCES

1. Farage MA. Does sensitive skin differ between men and women? Cutan Ocul Toxicol. 2010;29:153–63.

2. Farage MA. Perceptions of sensitive skin: changes in perceived severity and associations with environmental causes. Contact Dermatitis. 2008;59:226–32.

3. Farage MA. How do perceptions of sensitive skin differ at different anatomical sites? An epidemiological study. Clin Exp Dermatol. 2009;34:e521–30.

4. Willis CM, Shaw S, De Lacharrière O, et al. Sensitive skin: an epidemiological study. Br J Dermatol. 2001;145:258–63.

5. Bornkessel A, Flach M, Arens-Corell M, Elsner P, Fluhr JW. Functional assessment of a washing emulsion for sensitive skin: mild impairment of stratum corneum hydration, pH, barrier function, lipid content, integrity and cohesion in a controlled washing test. Skin Res Technol. 2005;11:53–60.

6. Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer M. Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol. 2011;41:1883–93.

7. Lin TK, Man MQ, Santiago JL, et al. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J Invest Dermatol. 2013;133:469–78.

8. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol. 2008;8:935–47.

9. Proksch E, Brasch J, Sterry W. Integrity of the permeability barrier regulates epidermal Langerhans cell density. Br J Dermatol. 1996;134:630–8.

10. Seidenari S, Francomano M, Mantovani L. Baseline biophysical parameters in subjects with sensitive skin. Contact Dermatitis. 1998;38:311–5.

11. Pinto P, Rosado C, Parreirão C, Rodrigues LM. Is there any barrier impairment in sensitive skin?: a quantitative analysis of sensitive skin by mathematical modeling of transepidermal water loss desorption curves. Skin Res Technol. 2011;17:181–5.

12. Muizuddin N, Marenus KD, Maes DH. Factors defining sensitive skin and its treatment. Am J Contact Dermat. 1998;9:170–5.

13. Cho HJ, Chung BY, Lee HB, Kim HO, Park CW, Lee CH. Quantitative study of stratum corneum ceramides contents in patients with sensitive skin. J Dermatol. 2012;39:295–300.

14. Issachar N, Gall Y, Borell MT, Poelman MC. pH measurements during lactic acid stinging test in normal and sensitive skin. Contact Dermatitis. 1997;36:152–5.

15. Hernández-Blanco D, Castanedo-Cázares JP, Ehnis-Pérez A, Jasso-Ávila L, Conde-Salazar L, Torres-Álvarez B. Prevalence of sensitive skin and its biophysical response in a Mexican population. World J Dermatol. 2013;2:1–7.

16. Tsai JC, Feingold KR, Crumrine D, Wood LC, Grunfeld C, Elias PM. Permeability barrier disruption alters the localization and expression of TNF alpha/protein in the epidermis. Arch Dermatol Res. 1994;286:242–8.

17. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest. 1992;90:482–7.

18. Wood LC, Stalder AK, Liou A, et al. Barrier disruption increases gene expression of cytokines and the S5 kD TNF receptor in murine skin. Exp Dermatol. 1997;6:98–104.

19. Wood LC, Elias PM, Sequeira-Martin SM, Grunfeld C, Feingold KR. Occlusion lowers cytokine mRNA levels in essential fatty acid-deficient and normal mouse epidermis, but not after acute barrier disruption. J Invest Dermatol. 1994;103:834–8.

20. Wood LC, Elias PM, Calhoun C, Tsai JC, Grunfeld C, Feingold KR. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J Invest Dermatol. 1996;106:397–403.

21. Proksch E, Brasch J. Influence of epidermal permeability barrier disruption and Langerhans’ cell density on allergic contact dermatitis. Acta Derm Venereol. 1997;77:102–4.

22. Katoh N, Hirano S, Kishimoto S, Yasuno H. Acute cutaneous barrier perturbation induces maturation of Langerhans’ cells in hairless mice. Acta Derm Venereol. 1997;77:365–9.

23. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol. 1997;109:175–82.
24. Pons-Guiraud A. Sensitive skin: a complex and multifactorial syndrome. J Cosmet Dermatol. 2004;3:145–8.

25. Inami Y, Andoh T, Sasaki A, Kuraishi Y. Surfactant-induced itching and the involvement of histamine released from keratinocytes. Yakugaku Zasshi. 2012;132:1225–30.

26. Gschwandtner M, Mildner M, Mlitz V, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy. 2013;68:37–47.

27. Gutowska-Owsiak D, Salimi M, Selvakumar TA, Wang X, Taylor S, Ogg GS. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function. J Investig Allergol Clin Immunol. 2014;24:231–9.

28. Scharschmidt TC, Man MQ, Hatano Y, et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol. 2009;124:496–506.

29. Roussaki-Schulze AV, Zafiriou E, Nikoulis D, Klimi E, Rallis E, Zintzaras E. Objective biophysical findings in patients with sensitive skin. Drugs Exp Clin Res. 2005;31S:17–24.

30. Issachar N, Gall Y, Borrel MT, Poelman MC. Correlation between percutaneous penetration of methyl nicotinate and sensitive skin, using laser Doppler imaging. Contact Dermatitis. 1998;39:182–6.

31. Berardesca E, Cespa M, Farinelli N, Rabbiosi G, Maibach H. In vivo transepidermal penetration of nicotinates and sensitive skin. Contact Dermatitis. 1991;25:35–8.

32. https://rationale.com/expert-advice/protocol-sensitive-skin. Accessed Sept 30, 2015.

33. Berardesca E, Farage M, Maibach H. Sensitive skin: an overview. Int J Cosmet Sci. 2013;35:2–8.

34. http://www.cosdna.com/eng/cosmetic_bb28121729.html. Accessed Jan 12, 2016.

35. http://www.physiogel.com/sg[Date]. Accessed Sept 30, 2015.

36. Man MQ, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Investig Dermatol. 1996;106:1096–101.

37. Yang L, Mao-Qiang M, Taljebini M, Elias PM, Feingold KR. Topical stratum corneum lipids accelerate barrier repair after tape stripping, solvent treatment and some but not all types of detergent treatment. Br J Dermatol. 1995;133:679–85.

38. Man MQ, Elias P, Feingold KR, Thornfeldt CR, Elias PM. A natural lipid mixture improves barrier function and skin hydration in both human and murine skin. J Soc Cosmet Chem. 1997;47:157–66.

39. Wang F, Man MQ, Elias P. A natural lipid mixture improves skin hydration in ichthyosis vulgaris. Int J Dermatol. 1997;36:876–7.

40. Rim JH, Jo SJ, Park JY, Park BD, Youn JI. Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol. 2005;30:409–13.

41. Kikuchi K, Kobayashi H, Hirao T, Ito A, Takahashi H, Tagami H. Improvement of mild inflammatory changes of the facial skin induced by winter environment with daily applications of a moisturizing cream. A half-side test of biophysical skin parameters, cytokine expression pattern and the formation of cornified envelope. Dermatology. 2003;207:269–75.

42. Vie K, Pons-Guiraud A, Dupuy P, Maibach H. Tolerance profile of a sterile moisturizer and moisturizing cleanser in irritated and sensitive skin. Am J Contact Dermat. 2000;11:161–4.

43. Weber TM, Ceilley RI, Buerger A, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol. 2006;5:227–32.

44. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47:198–208.

45. Sasaki T, Fujii K, Yoshida K, et al. Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells. Virchows Arch. 2006;448:422–7.

46. Mao-Qiang M, Fowler AJ, Schmuth M, et al. Peroxisome-proliferator-activated receptor [PPAR]-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol. 2004;123:305–12.

47. Laureles LR, Rodriguez FM, Reaño CE, Santos GA, Laurena AC, Mendoza EM. Variability in fatty acid and triacylglycerol composition of the oil of coconut (Cocos nucifera L.) hybrids and their parentals. J Agric Food Chem. 2002;50:1581–6.

48. Israel MO. Effects of topical and dietary use of shea butter on animals. Am J Life Sci. 2014;2:303–7.
49. Rubio M, Alvarez-Ortí M, Alvarruiz A, Fernández E, Pardo JE. Characterization of oil obtained from grape seeds collected during berry development. J Agric Food Chem. 2009;57:2812–5.

50. Jerajani HR, Mizoguchi H, Li J, Whittenbarger DJ, Marmor MJ. The effects of a daily facial lotion containing vitamins B3 and E and provitamin B5 on the facial skin of Indian women: a randomized, double-blind trial. Indian J Dermatol Venereol Leprol. 2010;76:20–6.

51. Bourguignon LY, Wong G, Xia W, Man MQ, Holleran WM, Elias PM. Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction. J Dermatol Sci. 2013;72:32–44.

52. Bourguignon LY, Ramez M, Gilad E, et al. Hyaluronan-CD44 interaction stimulates keratinocyte differentiation, lamellar body formation/secretion, and permeability barrier homeostasis. J Invest Dermatol. 2006;126:1356–65.

53. Lee SE, Jung MK, Oh SJ, Jeong SK, Lee SH. Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment. Arch Dermatol Res. 2013;307:781–92.

54. Man MQ, Choi EH, Schmuth M, et al. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Investig Dermatol. 2006;126:386–92.

55. Sheu MY, Fowler AJ, Kao J, et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Investig Dermatol. 2002;118:94–101.

56. Denda M, Sato J, Masuda Y, et al. Exposure to a dry environment enhances epidermal permeability barrier function. J Investig Dermatol. 1998;111:858–63.

57. Chou TC, Lin KH, Wang SM, et al. Transepidermal water loss and skin capacitance alterations among workers in an ultra-low humidity environment. Arch Dermatol Res. 2005;296:489–95.

58. Song EJ, Lee JA, Park JJ, et al. A study on seasonal variation of skin parameters in Korean males. Int J Cosmet Sci. 2015;37:92–7.

59. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci. 1996;85:643–8.

60. Elias PM, Tsai J, Menon GK, Holleran WM, Feingold KR. The potential of metabolic interventions to enhance transdermal drug delivery. J Investig Dermatol Symp Proc. 2002;7:79–85.

61. Fartasch M, Schnetz E, Diepgen TL. Characterization of detergent-induced barrier alterations—effect of barrier cream on irritation. J Investig Dermatol Symp Proc. 1998;3:121–7.

62. Garcia Bartels N, Lünnemann L, Stroux A, Kottner J, Serrano J, Blume-Peytavi U. Effect of diaper cream and wet wipes on skin barrier properties in infants: a prospective randomized controlled trial. Pediatr Dermatol. 2014;31:683–91.

63. Peltonen JM, Pylkkänen L, Jansén CT, et al. Three randomised phase I/IIa trials of 5% cis-urocanic acid emulsion cream in healthy adult subjects and in patients with atopic dermatitis. Acta Derm Venereol. 2014;94:415–20.

64. Buraczewska I, Berne B, Lindberg M, Törmä H, Lodén M. Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial. Br J Dermatol. 2007;156:492–8.